Interaction of an anti-HIV peptide, T22, with gp120 and CD4

Biochem Biophys Res Commun. 1996 Feb 15;219(2):555-9. doi: 10.1006/bbrc.1996.0272.

Abstract

T22 ([Tyr5,12, Lys7]-polyphemusin II) has been shown to have strong anti-human immunodeficiency virus (HIV) activity. The precise mechanism of action of T22 on HIV-replication has not been elucidated yet, nor have the targets of T22 been identified. However, our previous research suggested that T22 exerts its effect by blocking virus-cell fusion and that T22 might interact with an HIV envelope protein and/or a T-cell surface protein. Herein we use a novel biosensor based on the principles of surface plasmon resonance (BIAcore) to demonstrate that T22 binds specifically to both gp120 (an envelope protein of HIV) and CD4 (a T-cell surface protein) and that both bindings can be inhibited by an anti-T22 antibody. The data obtained suggest that T22 inhibits virus-cell fusion through the double binding to the above two proteins.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amino Acid Sequence
  • Antimicrobial Cationic Peptides*
  • Antiviral Agents / metabolism*
  • Antiviral Agents / pharmacology
  • Baculoviridae
  • Biosensing Techniques
  • CD4 Antigens / drug effects
  • CD4 Antigens / metabolism*
  • Cell Line
  • HIV Envelope Protein gp120 / metabolism*
  • HIV-1 / drug effects*
  • Humans
  • Kinetics
  • Membrane Fusion / drug effects
  • Molecular Sequence Data
  • Peptides / metabolism*
  • Peptides / pharmacology
  • Protein Binding
  • Recombinant Proteins / drug effects
  • Recombinant Proteins / metabolism
  • Sequence Homology, Amino Acid
  • T-Lymphocytes / immunology
  • T-Lymphocytes / virology

Substances

  • Antimicrobial Cationic Peptides
  • Antiviral Agents
  • CD4 Antigens
  • HIV Envelope Protein gp120
  • Peptides
  • Recombinant Proteins
  • T22 protein, synthetic